Working... Menu
Trial record 42 of 57 for:    Romidepsin | Phase 2

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01947140
Recruitment Status : Recruiting
First Posted : September 20, 2013
Last Update Posted : May 9, 2019
Information provided by (Responsible Party):
Jennifer Amengual, Columbia University